105 related articles for article (PubMed ID: 12460785)
1. Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours.
de Jonge MJ; Verweij J; van der Gaast A; Valota O; Mora O; Planting AS; Mantel MA; Bosch SV; Lechuga MJ; Fiorentini F; Hess D; Sessa C
Eur J Cancer; 2002 Dec; 38(18):2407-15. PubMed ID: 12460785
[TBL] [Abstract][Full Text] [Related]
2. Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation.
Moneta D; Geroni C; Valota O; Grossi P; de Jonge MJ; Brughera M; Colajori E; Ghielmini M; Sessa C
Eur J Cancer; 2003 Mar; 39(5):675-83. PubMed ID: 12628848
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.
Geroni C; Ripamonti M; Arrigoni C; Fiorentini F; Capolongo L; Moneta D; Marchini S; Della Torre P; Albanese C; Lamparelli MG; Ciomei M; Rossi R; Caruso M
Cancer Res; 2001 Mar; 61(5):1983-90. PubMed ID: 11280756
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
de Jonge MJ; Dumez H; Verweij J; Yarkoni S; Snyder D; Lacombe D; Marréaud S; Yamaguchi T; Punt CJ; van Oosterom A;
Eur J Cancer; 2006 Aug; 42(12):1768-74. PubMed ID: 16815702
[TBL] [Abstract][Full Text] [Related]
5. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.
Pasello M; Hattinger CM; Stoico G; Manara MC; Benini S; Geroni C; Mercuri M; Scotlandi K; Picci P; Serra M
Eur J Cancer; 2005 Sep; 41(14):2184-95. PubMed ID: 16140527
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
7. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
8. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
Gerrits CJ; Burris H; Schellens JH; Planting AS; van den Burg ME; Rodriguez GI; van Beurden V; Loos WJ; Hudson I; Fields S; Verweij J; von Hoff DD
Eur J Cancer; 1998 Jun; 34(7):1030-5. PubMed ID: 9849451
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
de Jong RS; Mulder NH; Uges DR; Sleijfer DT; Höppener FJ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):882-7. PubMed ID: 10070885
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Tolcher AW; Eckhardt SG; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky EK
J Clin Oncol; 2001 Jun; 19(11):2937-47. PubMed ID: 11387367
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.
de Jonge MJ; Kaye S; Verweij J; Brock C; Reade S; Scurr M; van Doorn L; Verheij C; Loos W; Brindley C; Mistry P; Cooper M; Judson I
Br J Cancer; 2004 Oct; 91(8):1459-65. PubMed ID: 15452551
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
Schwartz GH; Patnaik A; Hammond LA; Rizzo J; Berg K; Von Hoff DD; Rowinsky EK
Ann Oncol; 2003 May; 14(5):775-82. PubMed ID: 12702533
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
Ten Tije AJ; Verweij J; Sparreboom A; Van Der Gaast A; Fowst C; Fiorentini F; Tursi J; Antonellini A; Mantel M; Hartman CM; Stoter G; Planting AS; De Jonge MJ
Clin Cancer Res; 2003 Aug; 9(8):2957-64. PubMed ID: 12912942
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
